JP2001502903A - レンチウィルスベクター - Google Patents
レンチウィルスベクターInfo
- Publication number
- JP2001502903A JP2001502903A JP10519087A JP51908798A JP2001502903A JP 2001502903 A JP2001502903 A JP 2001502903A JP 10519087 A JP10519087 A JP 10519087A JP 51908798 A JP51908798 A JP 51908798A JP 2001502903 A JP2001502903 A JP 2001502903A
- Authority
- JP
- Japan
- Prior art keywords
- retroviral vector
- promoter
- region
- vector
- retrovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims abstract description 125
- 241000713666 Lentivirus Species 0.000 title claims abstract description 31
- 239000002245 particle Substances 0.000 claims abstract description 47
- 230000001177 retroviral effect Effects 0.000 claims abstract description 42
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 19
- 238000010361 transduction Methods 0.000 claims abstract description 8
- 230000026683 transduction Effects 0.000 claims abstract description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 241001430294 unidentified retrovirus Species 0.000 claims description 33
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 238000001415 gene therapy Methods 0.000 claims description 12
- 230000035897 transcription Effects 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 12
- 230000010354 integration Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 108020003215 DNA Probes Proteins 0.000 claims 1
- 239000003298 DNA probe Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 17
- 241000714177 Murine leukemia virus Species 0.000 description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 102100034353 Integrase Human genes 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 101710149951 Protein Tat Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 102100027887 Deaminated glutathione amidase Human genes 0.000 description 4
- 101000632167 Homo sapiens Deaminated glutathione amidase Proteins 0.000 description 4
- 108010061833 Integrases Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241001559589 Cullen Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 101150082061 nit-4 gene Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000996087 Homo sapiens Omega-amidase NIT2 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101000996085 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Nitrogen catabolic enzyme regulatory protein Proteins 0.000 description 1
- 101100516674 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nit-6 gene Proteins 0.000 description 1
- 101100238248 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nit-8 gene Proteins 0.000 description 1
- 102100034446 Omega-amidase NIT2 Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 101150025351 nit-3 gene Proteins 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 第1のレトロウィルスに基づくレトロウィルスベクター粒子であって、該 レトロウィルスベクター粒子は非分裂性の哺乳動物標的細胞に感染して形質導入 を生じさせることができ、該レトロウィルスベクター粒子はDNAプロウィルス の形態にある場合に標的細胞ゲノムに挿入され得るパッケージング可能なRNA ゲノムを含み、該RNAゲノムは該DNAプロウィルス内に: a)該第1のレトロウィルスのプロモーター機能に置き換わってプロウィルス の5'側ロングターミナルリピート(LTR)内に配置される非レンチウィルス発現制 御要素;および b)a)の非レンチウィルス発現制御要素の転写制御下におかれ、該LTRの間 に配置される1つまたは複数の所定の遺伝子 を提供する配列を含む、上記のレトロウィルスベクター粒子。 2. 前記第1のレトロウィルスがレンチウィルスであり、前記DNAプロウィ ルスに通常であれば5'側レンチウィルスタンパク質依存性プロモーター機能をも たらす1つまたは複数のレンチウィルス配列が存在していない、請求項1に記載 のレトロウィルスベクター粒子。 3. ベクターの基礎となる前記レンチウィルスがHIVであり、機能性TAR配列が 存在していない、請求項1または2に記載のレトロウィルスベクター粒子。 4. 前記ベクターゲノムが機能性revおよびRRE配列をさらに含んで、該ゲノム のRRE含有RNA転写産物を標的細胞の核から細胞質に輸送することを可能にす る、請求項3に記載のレトロウィルスベクター粒子。 5. レンチウィルスR領域が非レンチウィルスR領域に置き換えられる、請求 項2〜4のいずれか1項に記載のレトロウィルスベクター粒子。 6. 前記非レンチウィルス発現制御要素が、非レンチウィルス調節因子により 誘導可能な調節プロモーターである、請求項1〜5のいずれか1項に記載のレト ロウィルスベクター粒子。 7. 前記調節プロモーターが非ウィルス性調節因子により誘導可能である、請 求項6に記載のレトロウィルスベクター粒子。 8. 前記発現制御要素がMLV LTRプロモーターを含む、請求項1に記載のレト ロウィルスベクター粒子。 9. 前記非レンチウィルス発現制御要素が、レンチウィルス以外の、レトロウ ィルスのU3領域およびR領域、またはそれらの機能性部分を含む、請求項1〜8 のいずれか1項に記載のレトロウィルスベクター粒子。 10. 前記RNAゲノムが、第1の非レンチウィルスR領域、組込みおよび逆転 写のために十分なレンチウィルスU5領域部分、第一鎖の逆転写のためのプライマ ー結合部位、パッケージングシグナル、少なくとも1つの所定の遺伝子を含む内 部領域、第二鎖の逆転写のためのプライマー結合部位、組込みに十分なレンチウ ィルスU3領域の短い配列、非レンチウィルスプロモーター、ならびに該第1のR 領域と実質的に同一の第2のR領域を含む、請求項2〜9のいずれか1項に記載 のレトロウィルスベクター粒子。 11. プロモーターと作動可能に連結された、請求項1〜10のいずれか1項に記 載のレトロウィルスベクター粒子のパッケージング可能なRNAゲノムをコード する、DNA構築物。 12. 前記プロモーターが高効率プロモーターである、請求項11に記載のDNA 構築物。 13. 前記所定の遺伝子が存在せず、前記構築物が1つまたは複数の所定の遺伝 子を挿入しうる挿入部位を有する、請求項11または12に記載のDNA構築物。 14. 請求項11〜13のいずれか1項に記載のDNA構築物でトランスフェクトま たは形質導入された宿主細胞を含み、請求項1〜10のいずれか1項に記載のレト ロウィルスベクター粒子を産生可能な、レトロウィルスベクター粒子産生系。 15. 請求項1〜10のいずれか1項に記載のレトロウィルスベクター粒 子の成分をコードする核酸配列のセットを含む、レトロウィルスベクター粒子産 生系。 16. 遺伝子治療のために標的細胞に感染させて形質導入を生じさせるための、 請求項1〜10のいずれか1項に記載のレトロウィルスベクター粒子の使用。 17. 遺伝子治療に用いる薬剤の調製における、請求項1〜10のいずれか1項に 記載のレトロウィルスベクター粒子の使用。 18. 請求項1〜10のいずれか1項に記載のレトロウィルスベクター粒子を標的 細胞に感染させて形質導入を生じさせることを含む、該標的細胞に対して遺伝子 治療を行う方法。 19. 請求項16〜18のいずれか1項に記載の使用または方法によって得られる標 的細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9621680.9 | 1996-10-17 | ||
GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001502903A true JP2001502903A (ja) | 2001-03-06 |
Family
ID=10801598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10519087A Ceased JP2001502903A (ja) | 1996-10-17 | 1997-10-17 | レンチウィルスベクター |
Country Status (18)
Country | Link |
---|---|
US (1) | US6235522B1 (ja) |
EP (1) | EP0939827B1 (ja) |
JP (1) | JP2001502903A (ja) |
KR (1) | KR20000049250A (ja) |
CN (1) | CN1195864C (ja) |
AT (1) | ATE520783T1 (ja) |
AU (1) | AU737801B2 (ja) |
BG (1) | BG103334A (ja) |
CA (1) | CA2268271A1 (ja) |
CZ (1) | CZ137299A3 (ja) |
GB (2) | GB9621680D0 (ja) |
HK (1) | HK1018481A1 (ja) |
HU (1) | HUP0000442A3 (ja) |
IL (1) | IL128564A0 (ja) |
NO (1) | NO991742L (ja) |
NZ (1) | NZ334522A (ja) |
PL (1) | PL332876A1 (ja) |
WO (1) | WO1998017816A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508184A (ja) * | 1997-12-12 | 2002-03-19 | セル ジェネシス,インコーポレイティド | 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段 |
KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
WO1998051810A1 (en) | 1997-05-13 | 1998-11-19 | University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
ES2245042T3 (es) | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | Vectores de lentivirus de no primates y sistemas de empaquetamiento. |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
EP1088086A4 (en) | 1998-06-24 | 2003-01-08 | Musc Found For Res Dev | RIBOZYMES SPECIFIC TO TISSUE AND TARGET RNA |
US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
EP1849873B1 (en) * | 1999-04-29 | 2011-10-12 | Gbp Ip, Llc | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1083230A1 (en) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
EP1702983A3 (en) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
DK1282702T3 (da) * | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
AU2001263160A1 (en) | 2000-05-19 | 2001-12-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution |
WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
WO2002086064A2 (en) * | 2001-04-20 | 2002-10-31 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
WO2002087341A1 (en) * | 2001-05-01 | 2002-11-07 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (sin) lentiviral vectors |
ATE527347T1 (de) * | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
NZ532060A (en) * | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
EP2348119B1 (en) | 2002-02-01 | 2017-04-26 | Oxford BioMedica (UK) Limited | Multicistronic lentiviral vector |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
DE60326444D1 (de) * | 2002-04-26 | 2009-04-16 | Inst Clayton De La Rech | Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren |
EP1563069B1 (en) * | 2002-11-22 | 2012-06-06 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
WO2005030927A2 (en) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Methods and compositions for in vivo inflammation monitoring |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
DK3889173T3 (da) | 2013-02-15 | 2023-10-09 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
WO2014142235A1 (ja) * | 2013-03-13 | 2014-09-18 | Li Zhong | 微小胞及びその製造方法 |
EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
SG10201913278PA (en) | 2016-02-01 | 2020-02-27 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
AR110677A1 (es) | 2016-10-12 | 2019-04-24 | Bioverativ Usa Inc | Anticuerpos anti-c1s y métodos para usarlos |
KR102539159B1 (ko) | 2016-11-07 | 2023-06-02 | 주식회사 뉴라클사이언스 | 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법 |
JP7012384B2 (ja) | 2017-06-27 | 2022-02-14 | ニューラクル サイエンス カンパニー リミテッド | 癌治療のための抗fam19a5抗体の用途 |
EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
CN110972463B (zh) | 2017-06-27 | 2024-05-28 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5抗体在治疗青光眼中的用途 |
BR112019027729A2 (pt) | 2017-06-27 | 2020-08-18 | Neuracle Science Co., Ltd | anticorpos anti-fam19a5 e seus usos |
WO2019009979A1 (en) | 2017-07-06 | 2019-01-10 | The Medical College Of Wisconsin, Inc. | NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY |
CN111527105A (zh) | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
MX2020008152A (es) | 2018-02-01 | 2020-11-24 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor viii. |
AU2019259798A1 (en) | 2018-04-24 | 2020-11-12 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain |
AU2019265888A1 (en) | 2018-05-10 | 2020-11-26 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
CN113365650A (zh) | 2018-11-16 | 2021-09-07 | 新免疫技术有限公司 | 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法 |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
JP2022549932A (ja) | 2019-09-30 | 2022-11-29 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
WO2021146191A1 (en) | 2020-01-13 | 2021-07-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |
EP4093751A1 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
WO2021151006A2 (en) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Chimeric polypeptides |
JP2023512657A (ja) | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
EP4232566A1 (en) | 2020-10-22 | 2023-08-30 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
US20230398184A1 (en) | 2020-10-26 | 2023-12-14 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
KR20230104176A (ko) | 2020-11-02 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | 코로나바이러스의 치료를 위한 인터류킨-7의 용도 |
AU2021376396A1 (en) | 2020-11-05 | 2023-06-08 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
EP4347826A1 (en) | 2021-06-02 | 2024-04-10 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
WO2023056331A1 (en) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
JPH06510181A (ja) * | 1991-05-29 | 1994-11-17 | アメリカ合衆国 | Rnaプロセシングの調節機能を備えた真核細胞発現ベクター |
AU2419595A (en) * | 1994-05-10 | 1995-11-29 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
WO1995032300A1 (en) * | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
AU5103996A (en) * | 1995-03-09 | 1996-10-02 | Bavarian Nordic Research Institute A/S | Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
WO1997048277A1 (en) | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Application Discontinuation
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Application Discontinuation
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 EP EP97909437A patent/EP0939827B1/en not_active Expired - Lifetime
-
1999
- 1999-04-13 NO NO991742A patent/NO991742L/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
- 1999-08-17 HK HK99103561A patent/HK1018481A1/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508184A (ja) * | 1997-12-12 | 2002-03-19 | セル ジェネシス,インコーポレイティド | 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段 |
KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
CA2268271A1 (en) | 1998-04-30 |
GB9621680D0 (en) | 1996-12-11 |
IL128564A0 (en) | 2000-01-31 |
NO991742D0 (no) | 1999-04-13 |
NZ334522A (en) | 2001-11-30 |
WO1998017816A1 (en) | 1998-04-30 |
AU737801B2 (en) | 2001-08-30 |
ATE520783T1 (de) | 2011-09-15 |
GB2331522A (en) | 1999-05-26 |
EP0939827B1 (en) | 2011-08-17 |
EP0939827A1 (en) | 1999-09-08 |
HUP0000442A2 (hu) | 2000-06-28 |
HK1018481A1 (en) | 1999-12-24 |
NO991742L (no) | 1999-04-13 |
AU4712397A (en) | 1998-05-15 |
GB9903117D0 (en) | 1999-04-07 |
HUP0000442A3 (en) | 2001-09-28 |
BG103334A (en) | 2000-06-30 |
CN1195864C (zh) | 2005-04-06 |
GB2331522B (en) | 2001-05-23 |
PL332876A1 (en) | 1999-10-25 |
CN1234075A (zh) | 1999-11-03 |
US6235522B1 (en) | 2001-05-22 |
KR20000049250A (ko) | 2000-07-25 |
CZ137299A3 (cs) | 1999-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001502903A (ja) | レンチウィルスベクター | |
US7056699B2 (en) | Lentiviral LTR-deleted vector | |
Naldini et al. | Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. | |
JP6525986B2 (ja) | レトロウイルスベクター | |
Iwakuma et al. | Self-inactivating lentiviral vectors with U3 and U5 modifications | |
JP4418536B2 (ja) | レトロウイルスベクター | |
EP2194137B1 (en) | Cells comprising codon optimized lentiviral particles | |
JP4190579B2 (ja) | 非分裂細胞への核酸運搬のためのベクターおよび使用方法 | |
Kafri | Gene delivery by lentivirus vectors: an overview | |
KR20040054699A (ko) | 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물 | |
JP2000514652A (ja) | 産生能力の高いカプシド化系 | |
KR100246096B1 (ko) | 유전자 요법을 위한 개선된 레트로바이러스 벡터 | |
Matukonis et al. | Development of second-and third-generation bovine immunodeficiency virus-based gene transfer systems | |
Pandya et al. | Lentivirus and foamy virus vectors: novel gene therapy tools | |
Barker et al. | Vectors derived from the human immunodeficiency virus, HIV-1 | |
US6620595B2 (en) | Retroviral vectors comprising an enhanced 3′ transcription termination structure | |
JPH11507244A (ja) | Srv−3エンベロープ糖タンパク質配列で偽型化したレトロウイルスベクター | |
Molina et al. | Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector | |
ES2420842T3 (es) | Clones moleculares con genes mutados GAG/POL de VIH, GAG de VIS y ENV de VIS | |
KR20020003215A (ko) | 기능성 및 비기능성 스플라이스 도너와 스플라이스 억셉터사이트로 구성된 레트로바이러스 벡터 | |
Nguyen et al. | A Third-Generation Lentivirus Vector with | |
Barranger et al. | Concepts in Gene Therapy | |
JP2003501066A (ja) | Sivベースのパッケージング欠損ベクター |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070417 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071128 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080115 |